This therapeutic effect was further substantiated by a significant reduction in the protein levels of Col1a1 and fibronectin by using IHC analysis in the HepLPCs-treated rats, highlighting the therapeutic potential of HepLPCs in mitigating liver fibrosis (Fig. 2c, d). This evidence concerns the gene FN1 and Hepatic fibrosis.